

Guilherme Maradei

Guilherme has 25 years of experience in the pharmaceutical industry, with a solid track record of results-oriented leadership through performance turnarounds, restructurings, mergers & acquisitions and post-M&A integrations.

He currently serves as CEO of Biomm, a Brazilian publicly-listed biotechnology company focused on developing and commercializing biological/biosimilar products, leader in the Brazilian analog insulin market. Guilherme also serves as Advisory Board Member for Globo Pharma, a mid-sized private equity-backed pharmaceutical company focused on generics and branded generics, and as Board Member at Sindusfarma, the largest association of pharmaceutical manufacturers in Brazil, with over 600 company members.



From 2021 to 2025, he was CEO of Natulab, part of Patria Investments Private Equity. Previously, he was President of Merck Brazil from 2015 to 2019, and Vice President of Oncology in the United States from 2019 to 2021. He also served as General Manager of Valeant/Bausch & Lomb in Brazil from 2013 to 2015. Guilherme held leadership positions at Pfizer in New York and was a consultant at McKinsey & Company, where he worked with clients in the healthcare sector in Brazil and the United States.

Guilherme holds an MBA from the Kellogg School of Management at Northwestern University, where he graduated in 2005 with honors, and a bachelor's degree in Production Engineering from Escola Politecnica at University of São Paulo. He has lived, studied, and worked in São Paulo, Chicago, New York, New Jersey, Minneapolis, and Boston.